Evidence map›Paper›PMID 38875510›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Reply to J.A. Garcia et al.

Susan Halabi, Siyuan Guo, Akash Roy, Larysa E Rydzewska, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A Carducci and 10 more

Abstract readLetterComment

PubMed Full text at PMC Publisher

In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Comment on
Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?2024

5 · Who and what money

Authors and funding

20 authors.

Susan HalabiSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0003-4135-2777

Siyuan GuoSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-4372-9040

Akash RoySusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0001-6506-6156

Larysa E RydzewskaSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0001-6205-7457

Peter GodolphinSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0003-0648-0992

Maha HussainSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0003-0380-9465

Catherine TangenSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0001-8825-8660

Ian ThompsonSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.

Wanling XieSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0001-5995-8000

Michael A CarducciSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.

Michael J MorrisSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-9454-0096

Matthew R SmithSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.

Gwenaelle GravisSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-3127-1554

David P DearnaleySusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-3954-2806

Paul J VerhagenSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.

Takayuki J GotoSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.

Nick D JamesSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-7314-8204

Marc E BuyseSusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-4559-0994

Jayne F TierneySusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-4734-3014

Christopher J SweeneySusan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.ORCID 0000-0002-0398-6018

Funding

Research Triangle Center of Excellence in Regulatory Science and InnovationU01FD007857 · FDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HALABI, SUSAN, MENTZ, ROBERT JOHN · 2023 to 2025

$11.9M

Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCR01CA256157 · NCI · DUKE UNIVERSITY · PI ARMSTRONG, ANDREW J, DEHM, SCOTT M. · 2020 to 2025

$3.2M

Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerR01CA249279 · NCI · UNIVERSITY OF MINNESOTA · PI HALABI, SUSAN, SHARIFI, NIMA · 2021 to 2024

$2.1M

Sieve based full likelihood approach for the Cox proportional hazards model with applications to immunotherapies trialsR21CA263950 · NCI · DUKE UNIVERSITY · PI HALABI, SUSAN, WU, YUAN · 2023 to 2024

$405k

FDA HHS U01 FD007857NCI NIH HHS R01 CA249279NCI NIH HHS R01 CA256157NCI NIH HHS R21 CA263950

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38875510

DOI10.1200/JCO.24.00625

PMCPMC11346338

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.